Michael Tjong

🔥 Hot off the press: "Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT" ➡️In T2N0 glottic cancer, impaired vocal cord mobility is associated with worse LRF (aHR 3.7) and DFS (aHR 2.7) doi.org/10.1002/lary.7… @PMResearch_UHN @UofTDRO

🫁 International practice patterns for radiation planning and treatment of limited stage small cell lung cancer (LS-SCLC)🫁 🗣️Calling on the #lcsm #radonc community to participate in this survey from our team led by @UofTDRO @Sunnybrook @DrAlexLouie (PI) and Neelabh Rastogi (PGY-3 Resident) Study link and QR code below: surveymonkey.com/r/CYCCYC2 @drdavidpalma @mctjong @SALfaifi_

Similar model in last few years at @Sunnybrook #hncsm #radonc (not just NPC) w/ 1:1 RD + MD pairing from pre-treatment through follow-up with proactive weekly RD assessments during on-treatment review visits. Requires support as volumes and team grow but a worthwhile venture.

That’s David Harpole at #WCLC25 pointing out that with 70% already accrued to the VALOR study, more than 120 participants have already completed their 5y follow-up period. #CSP2005

Honored to support the very first World Radiotherapy Awareness Day today, September 7th! 🌍 By working together, we can ensure every person facing cancer has access to life-saving radiotherapy. #WorldRTDay @CamdenClarkMC 📚 Learn more: worldradiotherapy.org

☢️ Finally published the High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for LS-SCLC. ✅OS 43.5 versus 22.5 mo, (HR 0.68, 95% CI 0.48–0.98, p = 0.037) No more acute or late onset toxicity. ✅ Would you now consider 60 Gy bid the new standard of care? #LCSM @SclcSMASHERS ovid.com/journals/jton/…

Nasser Altorki's team publishes new data investigating the role of preop SBRT for NSCLC. This time, reporting their institutional data comparing preop SBRT-IO vs Chemo-IO. The results demonstrate a significant association with improved RFS at 2 years with SBRT delivered BEFORE immunotherapy (92% vs 64%, HR = 0.19). Technique = 8 Gy x 3, omiting the LNs doi.org/10.1016/j.jtcv…

New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. @rweichselbaum @SeanPitroda @dramycummings doi.org/10.1038/s43018…

It hit home as I returned to @Sunnybrook, where my own mother received cancer treatment with a message of HOPE to all who fight this disease. To help the more than 247,000 Canadians this year alone who will be diagnosed with cancer, I was proud to announce an ambitious plan to double the production of life-saving medical isotopes by 2030. Nuclear isotopes produce the essential treatments that help to destroy tumors and diagnose cancers earlier. The Nuclear Isotope Innovation Council of Ontario will save lives and create jobs — a legacy we can all get behind.

1/10 📢 Excited to share our new systematic review looking at risks and outcomes of definitive radiotherapy for patients with comorbid ILD and early-stage NSCLC! @IJROBP @Melissasamsoon @DrAlexLouie @HoudaBahig @drdavidpalma authors.elsevier.com/c/1lWCS1Hx52Ns…

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 @EORTC @ESTRO_RT @CiroFranzese1

❗️ Important work for SCLC 1-10 brain mets -> SRS mOS 10.2 m Only 22% of patients needed salvage WBRT Median 2 brain mets ascopubs.org/doi/10.1200/JC…

In @JCO_ASCO, our reflections on the timely ASCO TORS guideline @imrtlee @xrtGenomics 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status

📢 🚨#lungcancer peeps. Please consider Prof Andrea Bezjak from @UofT for your next IASLC president! A very deserving candidate and a great representative for #radonc!!! @ldawsonmd #lcsm

We are looking forward to some wonderful webinars coming up this month, including our very own ISRS President Arjun Sahgal! Check out our most recent newsletter to register for both webinars with @SahgalArjun and @DrAlexLouie, and see what else the ISRS has coming up! 👇 isrsy.org/?mailpoet_rout…

Congrats to @r_glicksman and the team @RadMedPM @RMPCRProgram @pmcancercentre for publishing this Ph2 single arm study of SBRT for OPD. 🔑1yr PFS 32%; median 4.7mo overall, different by histology 🔑1 patient had Gr3 tox; overall very well tolerated 🔑No significant decline in QOL @ScottBratman @ldawsonmd @DKirschMDPhD @Dr_AliHosni @JoannaJavor @aislingbarryro @RebeccaKSWong The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…

Should regional therapy be considered the preferred treatment approach in stage 2A/B seminoma? Read about our experience and approach @pmcancercentre @IJROBP @RHamiltonUrol @DiMariaJiang redjournal.org/article/S0360-…

"What is 'too old' for spine SBRT re: risk of vertebral compression fracture (VCF)?" is something colleagues and I debated at tumor boards on many occasions. We now have the answer (OPEN access) @IJROBP @UofTDRO @SahgalArjun #radonc #SBRT #sec0018" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl… 1/x

Must read clinical trials in the field of #SBRT 2024 Please complement the list, to allow us staying up-to-date !

"Oligo"-no more! 🇨🇦ARREST phase I out now @IJROBP - @sueyom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. shorturl.at/gStwt Congrats! 👏👏